Article info
PDFResponse
Ethical considerations for protecting the options of subjects in primary epidemic vaccine trials
- Correspondence to Dr Jerrold L Abraham, Pathology, SUNY Upstate Medical University, Syracuse, NY 13210, USA; abrahamj{at}upstate.edu
Citation
Ethical considerations for protecting the options of subjects in primary epidemic vaccine trials
Publication history
- Received August 26, 2020
- Accepted August 31, 2020
- First published September 17, 2020.
Online issue publication
March 10, 2023
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.
Other content recommended for you
- The UPTAKE study: a cross-sectional survey examining the insights and beliefs of the UK population on COVID-19 vaccine uptake and hesitancy
- Covid-19: Vaccine trials need more transparency to enable scrutiny and earn public trust, say experts
- Ethical considerations for epidemic vaccine trials
- Deciphering assumptions about stepped wedge designs: the case of Ebola vaccine research
- COVID-19 controlled human infection studies: worries about local community impact and demands for local engagement
- Efficacy and safety of an inactivated virus-particle vaccine for SARS-CoV-2, BIV1-CovIran: randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial
- Vaccines for older adults
- Covid-19: Researcher blows the whistle on data integrity issues in Pfizer’s vaccine trial
- Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial
- Phase II meningococcal B vesicle vaccine trial in New Zealand infants